¿Quieres mejorar el contenido de la página? Propón un cambio.
Most electronic vapour products contain nicotine, a developmental toxicant,
along with other harmful additives.
In 2015, among women in Oklahoma and Texas with a recent live birth:
| Used EVPs shortly before, during or after pregnancy | 7.0% |
| Used during pregnancy | 1.4% |
The number that matters most
Among those who used them during pregnancy:
| Reported the product contained nicotine | 38.4% |
| Did not know whether it contained nicotine | 26.4% |
**More than a quarter could not say whether they had been exposing a fetus to
nicotine.**
That is not carelessness. It is a straightforward product-information failure:
in 2015 the labelling of vapour products was inconsistent, the nicotine content
was frequently unstated or wrong, and a person buying one had no reliable way
to find out.
The consequence for advice is specific. Telling someone to avoid nicotine in
pregnancy assumes they can tell whether they are consuming it. For a quarter of
this group, that assumption did not hold — so the actionable advice is about
the product category rather than the ingredient.
And the remaining implication is arithmetic: **38.4% knew it had nicotine, 26.4%
did not know** — leaving about a third who believed it did not. Given what was
actually in these products, some of them were wrong.
Why the wider figure is included
The 7.0% covers shortly before, during or after pregnancy, against
1.4% during. Most women who used these products around a pregnancy did not
use them while pregnant — which says the message about pregnancy was reaching
people.
It also identifies where to intervene. A woman vaping before conception is the
one to reach, because stopping later is harder than not starting again; and
post-partum use matters for the household the infant is in.
Source: Centers for Disease Control and Prevention, MMWR.
Licencia: CC0 1.0 (dominio público) · Adaptado de www.cdc.gov
1
0
0
0

Comentarios

Sigue leyendo





